Completed PHASE1 INTERVENTIONAL 4-arm NCT04585347

Single Dose Study of ALZ-801 Prototype Tablets

Four-Period, Single-Dose, Sequential Study in Healthy Adults, to Assess Pharmacokinetics of ALZ-801 and Tramiprosate From ALZ-801 Prototype Tablets and Effect of Food on Bioavailability of ALZ-801 and Tramiprosate for Selected Prototype Tablet

Sponsor: Alzheon Inc.

Conditions Alzheimer Disease

Interventions ALZ-801 170 mg Fasting ALZ-801 205 mg After Food ALZ-801 205 mg Fasting ALZ-801 342 mg Fasting

Updated 4 times since 2020 Last updated: Oct 12, 2020 Started: Sep 16, 2015 Primary completion: Nov 13, 2015 Completion: Nov 13, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Alzheimer Disease and is currently completed. Alzheon Inc. leads this study, which shows 4 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Nov 2020 — Jan 2021 [monthly]

Completed PHASE1

First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alzheon Inc.
Quotient Clinical

Data source: Alzheon Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.